Eisai Thyroid Cancer Drug Gets Orphan Drug Status By U.S. FDA
This article was originally published in PharmAsia News
Executive Summary
Eisai Pharmaceuticals said its E7080 (lenvatinib) drug for treating thyroid cancer has been given orphan-drug status by U.S. FDA, easing its way through the marketing approval process.